Dynamin-1-Like Protein Inhibition Drives Megamitochondria Formation as an Adaptive Response in Alcohol-Induced Hepatotoxicity.


Journal

The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502

Informations de publication

Date de publication:
03 2019
Historique:
received: 31 01 2018
revised: 18 10 2018
accepted: 02 11 2018
pubmed: 17 12 2018
medline: 13 11 2019
entrez: 17 12 2018
Statut: ppublish

Résumé

Despite the growing global burden of alcoholic liver diseases, therapeutic options are limited, and novel targets are urgently needed. Accumulating evidence suggests that mitochondria adapt in response to ethanol and formation of megamitochondria in the livers of patients is recognized as a hallmark of alcoholic liver diseases. The processes involved in ethanol-induced hepatic mitochondrial changes, the impact on mitochondria-shaping proteins, and the significance of megamitochondria formation remain unknown. In this study, we investigated the mitochondrial and cellular response to alcohol in hepatoma cell line VL-17A. The mitochondrial architecture rapidly changed after 3 or 14 days of ethanol exposure with double-pronged presentation of hyperfragmentation and megamitochondria, and cell growth was inhibited. Dynamin-1-like protein (Drp1) was identified as the main mediator driving these mitochondrial alterations, and its genetic inactivation was determined to foster megamitochondria development, preserving the capacity of the cells to grow despite alcohol toxicity. The role of Drp1 in mediating megamitochondria formation in mice with liver-specific inactivation of Drp1 was further confirmed. Finally, when these mice were fed with ethanol, the presentation of hepatic megamitochondria was exacerbated compared with wild type fed with the same diet. Ethanol-induced toxicity was also reduced. Our study demonstrates that megamitochondria formation is mediated by Drp1, and this phenomenon is a beneficial adaptive response during alcohol-induced hepatotoxicity.

Identifiants

pubmed: 30553835
pii: S0002-9440(18)30112-3
doi: 10.1016/j.ajpath.2018.11.008
pmc: PMC6436109
pii:
doi:

Substances chimiques

Ethanol 3K9958V90M
Dnm1l protein, mouse EC 3.6.5.5
Dynamins EC 3.6.5.5

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

580-589

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA020518
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM118247
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA024733
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103549
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM123266
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Références

Crit Care Med. 2015 Feb;43(2):e38-47
pubmed: 25599491
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15803-8
pubmed: 18838687
J Biol Chem. 2012 Dec 7;287(50):42165-79
pubmed: 23086958
J Cell Biol. 1998 Oct 19;143(2):351-8
pubmed: 9786947
Gastroenterology. 2018 Sep;155(3):865-879.e12
pubmed: 29782848
Protoplasma. 2016 Sep;253(5):1299-308
pubmed: 26411562
J Dig Dis. 2012 Mar;13(3):133-42
pubmed: 22356308
Nat Commun. 2015 Aug 10;6:7882
pubmed: 26258887
Nature. 2008 Dec 4;456(7222):605-10
pubmed: 19052620
Dev Cell. 2008 Feb;14(2):193-204
pubmed: 18267088
Nat Rev Neurol. 2015 Jan;11(1):11-24
pubmed: 25486875
N Engl J Med. 2015 Apr 23;372(17):1619-28
pubmed: 25901427
Hum Mol Genet. 2013 Nov 15;22(22):4545-61
pubmed: 23813973
Br J Pharmacol. 2017 Jan;174(2):195-209
pubmed: 27861739
Cell Death Dis. 2014 Jul 17;5:e1328
pubmed: 25032851
Biochim Biophys Acta. 2015 Jul;1852(7):1400-9
pubmed: 25779081
Mol Biol Cell. 2004 Nov;15(11):5001-11
pubmed: 15356267
Biomed Res Int. 2014;2014:371593
pubmed: 24701574
Curr Pathobiol Rep. 2013 Sep 1;1(3):159-168
pubmed: 25343061
Invest Ophthalmol Vis Sci. 2011 Apr 27;52(5):2837-43
pubmed: 21372007
Am J Pathol. 1978 Feb;90(2):325-44
pubmed: 623205
Biochem Biophys Res Commun. 2012 Jan 6;417(1):262-7
pubmed: 22142844
Neurosci Lett. 2013 Jun 17;545:64-8
pubmed: 23628672
Science. 2012 Aug 31;337(6098):1062-5
pubmed: 22936770
Mol Biol Cell. 2001 Aug;12(8):2245-56
pubmed: 11514614
J Biomed Sci. 2001 Jan-Feb;8(1):20-7
pubmed: 11173972
Gastroenterology. 2014 May;146(5):1231-9.e1-6
pubmed: 24440674
EMBO J. 2014 Dec 1;33(23):2798-813
pubmed: 25349190
Dig Liver Dis. 2016 Jun;48(6):656-60
pubmed: 27026082
Hepatology. 2012 Jan;55(1):222-32
pubmed: 21932416
Gastroenterology. 2010 Nov;139(5):1740-52
pubmed: 20659474
Gastroenterology. 1977 Dec;73(6):1383-7
pubmed: 913978
Mol Biol Cell. 2013 Mar;24(5):659-67
pubmed: 23283981
J Clin Invest. 2009 May;119(5):1275-85
pubmed: 19349686
Cell Death Differ. 2012 Sep;19(9):1446-58
pubmed: 22388349
Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G324-40
pubmed: 26159696
Redox Biol. 2017 Aug;12:264-273
pubmed: 28282614
Hepatology. 1995 Sep;22(3):837-46
pubmed: 7657291
Eur J Clin Invest. 2017 Jul;47(7):531-539
pubmed: 28517024
Nat Protoc. 2007;2(2):287-95
pubmed: 17406588
Cell Death Dis. 2013 Mar 14;4:e540
pubmed: 23492771
Gastroenterology. 1971 Jun;60(6):1027-35
pubmed: 4104175
Int J Biochem Cell Biol. 2006 Jan;38(1):92-101
pubmed: 16181800
Am J Physiol Gastrointest Liver Physiol. 2014 Sep 15;307(6):G632-41
pubmed: 25080922
World J Gastroenterol. 2014 Mar 7;20(9):2136-42
pubmed: 24605012
N Engl J Med. 2013 Dec 5;369(23):2236-51
pubmed: 24304053
Gastroenterology. 1986 Jun;90(6):1858-64
pubmed: 3699404
Mol Neurobiol. 2016 Jan;53(1):240-253
pubmed: 25428621
Pflugers Arch. 2012 Jul;464(1):101-9
pubmed: 22526459
PLoS One. 2012;7(3):e33093
pubmed: 22427958
Cell Signal. 2011 Oct;23(10):1534-45
pubmed: 21683788
J Biol Chem. 2014 Dec 5;289(49):34074-88
pubmed: 25342755

Auteurs

Elena Palma (E)

The Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom; Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Xiaowen Ma (X)

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.

Antonio Riva (A)

The Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom; Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Valeria Iansante (V)

Institute of Liver Studies, King's College London, London, United Kingdom.

Anil Dhawan (A)

Institute of Liver Studies, King's College London, London, United Kingdom.

Shaogui Wang (S)

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.

Hong-Min Ni (HM)

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.

Hiromi Sesaki (H)

Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Roger Williams (R)

The Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom; Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Wen-Xing Ding (WX)

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.

Shilpa Chokshi (S)

The Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom; Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. Electronic address: s.chokshi@researchinliver.org.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH